RMB Capital Management LLC Sells 18,402 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

RMB Capital Management LLC lessened its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 64.1% during the 1st quarter, HoldingsChannel reports. The firm owned 10,287 shares of the biopharmaceutical company’s stock after selling 18,402 shares during the period. RMB Capital Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $1,171,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. AGF Investments LLC bought a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at about $25,000. Valeo Financial Advisors LLC bought a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter valued at about $52,000. Captrust Financial Advisors bought a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at about $75,000. Harvest Fund Management Co. Ltd lifted its stake in Ultragenyx Pharmaceutical by 15.9% in the 4th quarter. Harvest Fund Management Co. Ltd now owns 888 shares of the biopharmaceutical company’s stock valued at $122,000 after acquiring an additional 122 shares in the last quarter. Finally, CWM Advisors LLC bought a new stake in Ultragenyx Pharmaceutical in the 1st quarter valued at approximately $204,000. Institutional investors and hedge funds own 99.83% of the company’s stock.

Shares of NASDAQ RARE opened at $99.36 on Friday. The firm has a fifty day moving average price of $106.30. Ultragenyx Pharmaceutical Inc. has a one year low of $66.14 and a one year high of $179.65. The firm has a market cap of $6.71 billion, a price-to-earnings ratio of -31.85 and a beta of 1.91.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, May 4th. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by ($0.78). The company had revenue of $99.40 million for the quarter, compared to analyst estimates of $77.21 million. Ultragenyx Pharmaceutical had a negative return on equity of 38.24% and a negative net margin of 60.96%. The business’s revenue for the quarter was up 173.7% compared to the same quarter last year. During the same period last year, the company posted ($2.05) earnings per share. On average, sell-side analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.22 earnings per share for the current fiscal year.

In related news, EVP Camille L. Bedrosian sold 5,000 shares of the company’s stock in a transaction on Thursday, April 15th. The stock was sold at an average price of $109.09, for a total transaction of $545,450.00. Following the completion of the sale, the executive vice president now directly owns 44,139 shares in the company, valued at approximately $4,815,123.51. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Dennis Karl Huang sold 363 shares of the company’s stock in a transaction on Thursday, May 6th. The stock was sold at an average price of $113.68, for a total value of $41,265.84. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,901 shares of company stock worth $3,878,152. 6.70% of the stock is currently owned by insiders.

Several research firms have commented on RARE. Evercore ISI upgraded Ultragenyx Pharmaceutical from an “in-line” rating to an “outperform” rating and set a $144.00 target price on the stock in a research note on Wednesday, May 5th. JPMorgan Chase & Co. cut Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $165.00 price objective on the stock. in a research note on Friday, February 12th. TheStreet upgraded Ultragenyx Pharmaceutical from a “d” rating to a “c-” rating in a research note on Tuesday, February 16th. Citigroup upgraded Ultragenyx Pharmaceutical from a “neutral” rating to a “buy” rating and dropped their price objective for the stock from $160.00 to $151.00 in a research note on Thursday, May 6th. Finally, Zacks Investment Research cut Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating and set a $152.00 price objective on the stock. in a research note on Wednesday, February 17th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have given a buy rating to the company. Ultragenyx Pharmaceutical has an average rating of “Buy” and a consensus price target of $144.41.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders.

Featured Story: Stop Order Uses For Individual Investors

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.